A detailed history of Sargent Bickham Lagudis LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Sargent Bickham Lagudis LLC holds 33,843 shares of BMY stock, worth $1.66 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares
33,843
Previous 34,867 2.94%
Holding current value
$1.66 Million
Previous $2.48 Million 1.82%
% of portfolio
0.2%
Previous 0.22%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 23, 2023

SELL
$68.48 - $81.09 $70,123 - $83,036
-1,024 Reduced 2.94%
33,843 $0
Q3 2022

Oct 27, 2022

SELL
$0.13 - $76.84 $323 - $191,101
-2,487 Reduced 6.66%
34,867 $2.48 Million
Q2 2022

Jul 13, 2022

BUY
$72.62 - $79.98 $183,510 - $202,109
2,527 Added 7.26%
37,354 $2.88 Million
Q1 2022

Apr 27, 2022

SELL
$61.48 - $73.72 $581,846 - $697,686
-9,464 Reduced 21.37%
34,827 $2.54 Million
Q4 2021

Jan 18, 2022

SELL
$53.63 - $62.52 $1.34 Million - $1.56 Million
-25,027 Reduced 36.1%
44,291 $2.76 Million
Q3 2021

Nov 05, 2021

BUY
$59.17 - $69.31 $58,104 - $68,062
982 Added 1.44%
69,318 $4.1 Million
Q2 2021

Jul 19, 2021

BUY
$61.91 - $67.42 $132,487 - $144,278
2,140 Added 3.23%
68,336 $4.57 Million
Q1 2021

May 24, 2021

BUY
$59.34 - $66.74 $257,891 - $290,052
4,346 Added 7.03%
66,196 $4.18 Million
Q4 2020

May 24, 2021

SELL
$57.74 - $65.43 $250,938 - $284,358
-4,346 Reduced 6.57%
61,850 $3.84 Million
Q4 2020

May 24, 2021

BUY
$57.74 - $65.43 $324,845 - $368,109
5,626 Added 9.29%
66,196 $4.18 Million
Q3 2020

Sep 01, 2021

BUY
$57.43 - $63.64 $308,915 - $342,319
5,379 Added 9.75%
60,570 $3.65 Million
Q2 2020

Sep 07, 2021

BUY
$54.82 - $64.09 $2 Million - $2.34 Million
36,563 Added 196.28%
55,191 $3.25 Million
Q1 2020

Sep 07, 2021

SELL
$46.4 - $67.43 $36,516 - $53,067
-787 Reduced 4.05%
18,628 $1.04 Million
Q4 2019

Sep 14, 2021

BUY
$49.21 - $64.19 $58,756 - $76,642
1,194 Added 6.55%
19,415 $1.25 Million
Q3 2019

Sep 14, 2021

BUY
$42.77 - $50.71 $5,346 - $6,338
125 Added 0.69%
18,221 $924,000
Q2 2019

Sep 13, 2021

BUY
$44.62 - $49.34 $133 - $148
3 Added 0.02%
18,096 $821,000
Q1 2019

Sep 13, 2021

SELL
$45.12 - $53.8 $8,617 - $10,275
-191 Reduced 1.04%
18,093 $863,000
Q4 2018

Sep 13, 2021

BUY
$48.76 - $63.23 $13,555 - $17,577
278 Added 1.54%
18,284 $950,000
Q3 2018

Sep 13, 2021

SELL
$55.19 - $62.25 $31,458 - $35,482
-570 Reduced 3.07%
18,006 $1.12 Million
Q2 2018

Sep 13, 2021

SELL
$50.53 - $62.98 $40,171 - $50,069
-795 Reduced 4.1%
18,576 $1.03 Million
Q1 2018

Sep 13, 2021

SELL
$59.92 - $68.98 $19,474 - $22,418
-325 Reduced 1.65%
19,371 $1.23 Million
Q4 2017

Sep 13, 2021

BUY
$59.94 - $65.35 $33,806 - $36,857
564 Added 2.95%
19,696 $1.21 Million
Q3 2017

Sep 13, 2021

BUY
$55.23 - $63.74 $17,452 - $20,141
316 Added 1.68%
19,132 $1.22 Million
Q2 2017

Sep 13, 2021

SELL
N/A
-116 Reduced 0.61%
18,816 $1.05 Million
Q1 2017

Sep 13, 2021

SELL
N/A
-1,484 Reduced 7.27%
18,932 $1.03 Million
Q4 2016

Sep 13, 2021

SELL
N/A
-614 Reduced 2.92%
20,416 $1.19 Million
Q3 2016

Sep 13, 2021

SELL
N/A
-494 Reduced 2.3%
21,030 $1.13 Million
Q2 2016

Sep 07, 2021

SELL
N/A
-361 Reduced 1.65%
21,524 $1.58 Million
Q1 2016

Sep 07, 2021

BUY
N/A
21,885
21,885 $1.4 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $104B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Sargent Bickham Lagudis LLC Portfolio

Follow Sargent Bickham Lagudis LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sargent Bickham Lagudis LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sargent Bickham Lagudis LLC with notifications on news.